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Abstract
Background: Clinical surveillance of the prevalence of contact allergy in consecu-
tively patch tested patients is a proven instrument to continually assess the impor-
tance of contact allergens (haptens) assembled in a baseline series.
Objectives: To present current results from the European Surveillance System on
Contact Allergies, including 13 countries represented by 1 to 11 departments.
Methods: Anonymized or pseudonymized patch test and clinical data from various
data capture systems used locally or nationally as transferred to the Erlangen data
centre were pooled and descriptively analysed after quality control.
Results: In the 4 years (2015-2018), data from 51 914 patients patch tested with the
European baseline series (EBS) of contact allergens were analysed. Contact allergy to nickel
was most frequent (17.6% positive), followed by contact allergy to fragrance mix I (6.9%),
methylisothiazolinone (MI; 6.2%), andMyroxylon pereirae resin (balsam of Peru; 5.8%).
Conclusions: While the prevalence of MI contact allergy decreased substantially fol-
lowing regulatory intervention, the persistently high levels of allergy to metals, fra-
grances, other preservatives, and rubber chemicals point to problems needing further
research and, potentially, preventive efforts. Results with national additions to the
baseline series provide important information on substances possibly to be consid-
ered for inclusion in the EBS.
K E YWORD S
clinical epidemiology, contact allergy, patch testing, RRID:SCR_001905, surveillance
1 | INTRODUCTION
The value of surveillance of contact allergy using scientific networks
has been repeatedly illustrated (for example, see Uter et al 20201 for
a summary on this topic) and shall not be further expanded on. In the
United States and Canada, continual reporting by the North American
Contact Dermatitis Research Group, for example,2 provides a regular
audit of the value of patch testing, and of the importance of single
allergens (possibly in subgroups of the patch tested population) and
time trends, as does the work of the European Surveillance System on
Contact Allergies (ESSCA, https://www.essca-dc.org) in Europe.3 A
series of reports presenting results of patch testing with the European
baseline series (EBS; see4 for the current version) and partly also with
national or some local additions to it has been published. Continuing
this series, 4-year results, obtained from 2015 to 2018, are presented
and discussed herein.
2 | METHODS
The ESSCA is a working group of the ESCD (https://www.escd.org).
Its objective is the clinical surveillance of contact allergy.1,5 To this
end, contributing departments (Table S1) submit either all patch test
results or just patch test results obtained with the EBS (or national or local
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adaptations thereof), obtained following ESCD standards,6 to the data
centre in Erlangen. This is accompanied by important demographic and
clinical information, ranging from “MOAHLFA” characteristics to a wider
range of information according to the ESSCA minimal dataset defini-
tion.1,7 Data from contributing departments are delivered in an anony-
mous format or partly, following national network standards, in a
pseudonymized format, where the pseudonym cannot be related to actual
personal data except in the contributing department itself. This difference
is of importance, as only with pseudonymized data can re-investigations
of patients be identified and eliminated, to avoid duplication of entries.
For the purpose of the present analysis, a random selection among two or
more consultations documented in the database, involving testing the
baseline series, was made. Data were quality checked, providing an inter-
nal report for each contributing department for scrutiny and approval
before pooling of the respective data.5 Two departments contributed
aggregated (ie, no individual) data on results, stratified for gender, namely,
Gentofte/Denmark and Coimbra/Portugal. Test results with different
preparations of the same allergen, for example, concerning
methylisothiazolinone (MI), are presented separately. Concerning MI,
0.05% and 0.2% aqueous (aq.) had been tested most commonly. Follow-
ing an overall decline of patient numbers patch tested from 2015 to
2018, patch testing with MI 0.05% aq. also decreased, by 37.7%, whereas
patch testing with MI 0.2% aq. decreased by 29.1% (P < .0001, chi-square
test). Data management and analysis were performed with the R software
package (www.rproject.org; RRID:SCR_001905), version 3.6. For the cal-
culation of 95% confidence intervals (CIs) to zero proportions an approxi-
mation to an exact CI was used.8
Data from the subset of departments from Austria, Germany, and
Switzerland participating in the Information Network of Departments
of Dermatology (IVDK, https://ivdk.org/en) and in the ESSCA (these
departments roughly cover one-third of all investigations included in
the IVDK) were also included in the presentation of 2007 to 2018
IVDK results with the German baseline series recently published.9
3 | RESULTS
In total, data of 51 914 patients patch tested with the EBS from
2015 to 2018 (inclusive) were analysed. The individual contribu-
tion by country and department is shown in Table S1. Population
characteristics according to the MOAHLFA index,10 extended by
the P-measure, that is, the proportion of patients positive to at
least one allergen from the baseline series,11 are illustrated in
Table 1. The share of patients with one, two, and three or more
positive reactions to unrelated allergens12 applied in the baseline
series was 23.3%, 12%, and 16.8%, respectively. A considerable
variation of all MOAHLFA factors is evident. In the present data,
the share of patients aged 40 or older is just slightly higher in
males (62.9%) than in females (61.6%, P = .005). The overall share
of patients with trunk or generalized dermatitis was 5% and 5.6%,
respectively.
Patch test results with the EBS, in the version valid at the
time,13,14 are shown in Table 2 as crude overall prevalence and sex-
stratified prevalences, respectively. A supplemental analysis stratified
for three age groups is presented in Table S2 for the EBS and in
supplemental Table S3 for additions thereof. A further analysis pre-
senting age- and sex-standardized, instead of age- and sex-stratified,
results is presented in Table S4, for direct comparison with previous
ESSCA analyses using the same standardization.15 Patch testing
results to the three metals, the four fragrance allergens, and the
preservatives shown in Table 2 are as follows: 21.9% were positive
to at least one metal, 12.1% to at least one of the fragrance
markers, and 11.1% to at least one of the preservatives listed.
The currently used textile dye mix (TDM) 6.6% petrolatum (pet.)
contains Disperse Orange 3 1%, which strongly cross-reacts with
p-phenylenediamine (PPD). The cross-reactivity between TDM and
PPD was thus assessed: Of the 11 996 patients tested with both
TDM and PPD, 184 (1.5%) reacted to TDM and PPD, 152 (1.3%) only
to TDM, and 209 (1.7%) only to PPD. An odds ratio (OR) of 66.3
indicates very marked cross-reactivity.
In many departments temporary or long-term additions were
tested along with the EBS in consecutive patients; these results are
shown in Table 3 in a format identical to Table 2. “Carba mix” contains
not only two dithiocarbamates (zinc dibutyldithiocarbamate and zinc
diethyldithiocarbamate [ZDEC]) but also 1,3-diphenylguanidine. Of
18 796 patients patch tested with both thiuram and carba mix,
111 (0.59%) reacted to both, whereas 388 (2.06%) were positive only
to carba mix and 188 (1%) only to thiuram mix. Of all 500 positive
reactions to carba mix, 86.6% were weak positive, with the remainder
either strong (12.4%) or extreme (1%) positive. None of the patients
TABLE 1 Demographic and clinical characteristics according to the MOAHLFA index10 with “P-measure,”11 that is, the proportion of patients
with at least one positive reaction to a baseline series allergen, excluding one purely paediatric department (Padova Paediatric Department)
Factor Minimum % Average % Median % Maximum %
Male M 20.5 32.9 32.3 58.8
Occupational O 2.4 16.1 13.9 70.1
Atopic dermatitis A 7.5 27.5 21.7 70.5
Hand H 7.0 27.0 29.0 87.5
Leg L 0.0 5.3 5.8 19.3
Face F 1.4 17.9 18.1 39.0
Age 40+ A 35.2 62.6 65.1 77.5
Positive to at least one baseline series hapten P 35.0 52.1 53.1 80.0
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TABLE 2 Patch test results (days 3 to 5) with the European baseline series, 2015 to 2018, in the 48 active departments of the European
Surveillance System on Contact Allergies (ESSCA), additionally stratified for sex
Allergen Conc. Tested
%
?
+/IR % +
% +
+/+++ % positive (95% CI)
Females: % positive
(95% CI)
Males: % positive
(95% CI)
Metals
Potassium dichromate 0.5 48 610 3.43 2.11 1.7 3.73 (3.56-3.9) 3.39 (3.2-3.59) 4.42 (4.1-4.75)
Cobalt(II) chloride
hexahydrate
1 48 579 3.63 3.14 2.39 5.39 (5.19-5.6) 6.09 (5.84-6.36) 3.93 (3.63-4.24)
Nickel(II) sulfate hexahydrate 5 48 421 2.47 6.58 11.25 17.65 (17.31-17.99) 22.99 (22.53-23.45) 6.65 (6.26-7.04)
Fragrances
Fragrance mix I 8 47 697 2.53 3.92 3.05 6.95 (6.72-7.18) 7.49 (7.2-7.78) 5.82 (5.45-6.2)
Fragrance mix II 14 49 760 2.21 2.24 1.51 3.72 (3.56-3.89) 3.95 (3.75-4.17) 3.26 (2.99-3.55)
HICC 5 44 355 0.83 0.78 0.63 1.41 (1.3-1.53) 1.54 (1.4-1.68) 1.16 (0.99-1.35)
Myroxylon pereirae (balsam of
Peru)
25 44 687 2.82 3.77 2.24 5.8 (5.58-6.02) 5.86 (5.59-6.13) 5.68 (5.31-6.07)
Preservatives
Formaldehyde 1a 32 290 1.29 1.16 0.96 2.12 (1.97-2.28) 2.19 (2-2.39) 1.98 (1.73-2.27)
Formaldehyde 2a 16 989 0.79 0.98 1 1.98 (1.78-2.2) 2.14 (1.88-2.42) 1.65 (1.33-2.03)
MCI/MI 0.01a 38 345 1.35 2.49 2.23 4.73 (4.52-4.95) 4.99 (4.73-5.26) 4.19 (3.84-4.55)
MCI/MI 0.02a 10 566 5.44 2.9 2.86 5.74 (5.3-6.2) 6.28 (5.73-6.87) 4.6 (3.93-5.36)
Methylisothiazolinone 0.01a 709 1.51 0.99 1.27 2.26 (1.3-3.64) 2.61 (1.36-4.52) 1.55 (0.42-3.92)
Methylisothiazolinone 0.02a 4143 0.25 2.49 3.72 6.2 (5.49-6.98) 7.03 (6.15-7.99) 3.79 (2.72-5.12)
Methylisothiazolinone 0.05a 17 208 1.59 3.06 2.27 5.33 (5-5.68) 5.39 (4.98-5.83) 5.22 (4.68-5.8)
Methylisothiazolinone 0.2a 25 462 1.35 1.95 3.18 5.29 (5.02-5.57) 5.68 (5.34-6.03) 4.44 (4-4.91)
Paraben mix 16 47 093 1.22 0.43 0.21 0.61 (0.54-0.69) 0.47 (0.4-0.55) 0.9 (0.76-1.07)
Quaternium-15 1 29 481 0.23 0.38 0.34 0.7 (0.61-0.8) 0.79 (0.67-0.92) 0.51 (0.37-0.68)
Methyldibromo glutaronitrile 0.2 5058 2.33 1.23 0.42 1.64 (1.31-2.03) 1.28 (0.92-1.73) 2.28 (1.64-3.06)
Methyldibromo glutaronitrile 0.3 28 640 3.32 2.72 0.62 3.29 (3.09-3.51) 3.26 (3.02-3.53) 3.36 (3-3.74)
Methyldibromo glutaronitrile 0.5 13 687 2.9 0.71 3.49 3.89 (3.58-4.23) 3.61 (3.24-4) 4.54 (3.93-5.21)
Medicaments, excipients
Benzocaine 5 18 643 0.53 0.2 0.54 0.69 (0.58-0.82) 0.67 (0.54-0.83) 0.74 (0.53-1)
Clioquinol
(iodochlorhydroxyquine)
5 15 677 0.56 0.12 0.18 0.29 (0.21-0.38) 0.29 (0.2-0.41) 0.28 (0.15-0.48)
Budesonide 0.01 19 268 1.76 0.38 0.31 0.67 (0.56-0.8) 0.6 (0.48-0.74) 0.84 (0.62-1.11)
Budesonide 0.1 13 671 1.24 0.18 0.09 0.29 (0.21-0.4) 0.31 (0.21-0.45) 0.25 (0.13-0.45)
Tixocortol pivalate 0.1 20 849 1 0.27 0.28 0.56 (0.46-0.67) 0.53 (0.42-0.66) 0.62 (0.44-0.84)
Tixocortol pivalate 1 15 713 0.67 0.56 0.25 0.81 (0.68-0.97) 0.82 (0.66-1.01) 0.8 (0.57-1.09)
Neomycin sulfate 20 34 530 0.57 0.5 0.74 1.23 (1.11-1.35) 1.38 (1.23-1.53) 0.89 (0.72-1.09)
Lanolin (wool) alcohols 30 44 607 1.33 1.27 0.51 1.73 (1.61-1.86) 1.72 (1.58-1.88) 1.75 (1.54-1.97)
Rubber additives
Thiuram mix 1 48 416 0.87 0.85 1.04 1.91 (1.79-2.03) 1.79 (1.65-1.94) 2.15 (1.93-2.39)
N-isopropyl-N0-phenyl-p-
phenylene diamine
0.1 45 703 0.73 0.37 0.34 0.7 (0.62-0.78) 0.54 (0.46-0.63) 1.02 (0.86-1.19)
Mercapto mix (MBT, CBS,
MBTS, MOR)
2 27 416 0.25 0.21 0.24 0.46 (0.39-0.55) 0.43 (0.34-0.53) 0.55 (0.4-0.74)
Mercapto mix (CBS, MBTS,
MOR)
1 20 322 0.87 0.32 0.24 0.54 (0.45-0.65) 0.42 (0.32-0.55) 0.76 (0.57-0.99)
Mercaptobenzothiazole 2 48 706 0.6 0.27 0.26 0.52 (0.46-0.59) 0.46 (0.39-0.54) 0.66 (0.54-0.8)
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TABLE 2 (Continued)
Allergen Conc. Tested
%
?
+/IR % +
% +
+/+++ % positive (95% CI)
Females: % positive
(95% CI)
Males: % positive
(95% CI)
Resins/glues
Colophonium 20 48 694 1.09 1.33 1.8 3.11 (2.95-3.26) 3.25 (3.06-3.45) 2.81 (2.56-3.08)
Epoxy resin 1 47 014 0.64 0.54 0.72 1.24 (1.14-1.34) 0.85 (0.75-0.95) 2.05 (1.83-2.29)
PTBFR 1 34 453 0.7 0.31 0.31 0.64 (0.55-0.73) 0.68 (0.58-0.79) 0.54 (0.41-0.7)
Other
p-Phenylenediamine 1 37 377 0.77 1.28 2.18 3.44 (3.26-3.63) 4.02 (3.79-4.27) 2.13 (1.87-2.41)
Sesquiterpene lactone mix 0.1 27 963 0.75 0.31 0.46 0.8 (0.7-0.91) 0.8 (0.68-0.93) 0.82 (0.64-1.03)
Primin 0.01 22 031 1.39 0.12 0.17 0.28 (0.21-0.36) 0.34 (0.25-0.44) 0.13 (0.06-0.25)
Textile dye mix 6.6 14 021 3.74 0.8 2.04 2.77 (2.51-3.06) 3.03 (2.7-3.39) 2.21 (1.79-2.68)
Abbreviations: Conc., concentration in %, tested in petrolatum, except where otherwise indicated; CBS, N-Cyclohexylbenzothiazyl sulfenamide; HICC,
hydroxyisohexyl 3-cyclohexene carboxaldehyde; IR, irritant; MBT, 2-Mercaptobenzothiazole; MBTS, Dibenzothiazyl disulfide; MCI, methyl-
chloroisothiazolinone; MI, methylisothiazolinone; MOR, 2-(4-Morpholinylmercapto)benzothiazol; PTBFR, p-tert-butylphenol formaldehyde resin.
aAqueous (aq.).
TABLE 3 Patch test results (day 3 to day 5) with additions to the European baseline series, 2015 to 2018, in those departments of the
European Surveillance System on Contact Allergies (ESSCA) testing these in consecutive patients
Allergen Concentration Tested
%
?
+/IR % +
% +
+/+++
% positive
(95% CI)
Females: %
positive (95% CI)
Males: %
positive (95% CI)
Oil of turpentine 10.00 14 176 1.01 0.58 0.23 0.81 (0.67-0.97) 0.77 (0.6-0.98) 0.88 (0.64-1.17)
MDBGN + 2-phenoxyethanol 0.50 227 0.88 0.00 0.88 (0.11-3.15) 1.22 (0.15-4.34) 0 (0-5.69)
MDBGN + 2-phenoxyethanol 1.00 548 0.91 2.01 2.92 (1.68-4.7) 2.44 (1.12-4.58) 3.91 (1.59-7.89)
MDBGN + 2-phenoxyethanol 1.50 1820 0.62 0.22 0.16 0.38 (0.15-0.79) 0.26 (0.05-0.75) 0.62 (0.17-1.58)
Diazolidinyl urea 2.00 22 276 0.3 0.44 0.15 0.59 (0.49-0.7) 0.58 (0.46-0.71) 0.61 (0.44-0.83)
Imidazolidinyl urea 2.00 22 115 0.27 0.39 0.08 0.47 (0.38-0.56) 0.24 (0.03-0.85) 0 (0-1.16)
Imidazolidinyl urea 1.00 1167 0.17 0.00 0.17 (0.02-0.62) 0.48 (0.38-0.61) 0.41 (0.28-0.59)
2-Bromo-2-nitropropane-
1,3-diol
0.25 5805 0.25 0.78 0.14 0.91 (0.68-1.19) 0.98 (0.7-1.32) 0.75 (0.39-1.3)
2-Bromo-2-nitropropane-
1,3-diol
0.30 2525 0.04 0.00 0.51 0.51 (0.27-0.88) 0.76 (0.41-1.3) 0 (0-0.45)
2-Bromo-2-nitropropane-
1,3-diol
0.50 8454 0.19 0.35 0.15 0.51 (0.37-0.68) 0.51 (0.34-0.73) 0.51 (0.28-0.85)
Iodopropynyl butylcarbamate 0.20 22 978 3.29 1.03 0.13 1.17 (1.03-1.31) 1.12 (0.96-1.3) 1.25 (1.02-1.52)
Caine mix III (benzocaine,
dibucaine, tetracaine)
10.00 13 742 0.79 1.11 0.28 1.45 (1.26-1.66) 1.31 (1.09-1.57) 1.74 (1.37-2.17)
Propolis 10.00 21 807 3.6 2.36 0.60 2.96 (2.74-3.19) 2.9 (2.63-3.19) 3.07 (2.69-3.48)
Sodium metabisulfite 1.00 13 088 0.96 2.97 1.00 3.97 (3.64-4.32) 3.19 (2.84-3.57) 5.75 (5.05-6.51)
Fusidic acid, sodium salt 2.00 4585 0.13 0.15 0.02 0.17 (0.08-0.34) 0.22 (0.09-0.45) 0.07 (0-0.41)
Zinc diethyldithiocarbamate 1.00 15 605 0.39 0.35 0.25 0.6 (0.48-0.73) 0.59 (0.45-0.77) 0.6 (0.42-0.84)
Carba mix 3.00 19 792 1.64 2.27 0.35 2.61 (2.39-2.84) 1.97 (1.74-2.22) 4 (3.53-4.52)
Compositae mix 6.00 733 0.41 0.14 0.27 0.41 (0.08-1.19) 0.22 (0.01-1.2) 0.74 (0.09-2.63)
Compositae mix 5.00 15 354 0.88 0.85 0.59 1.45 (1.26-1.65) 1.27 (1.06-1.51) 1.74 (1.42-2.12)
Compositae mix 2.50 3306 0.16 0.15 0.33 0.48 (0.28-0.78) 0.53 (0.28-0.93) 0.38 (0.1-0.96)
Cetearyl alcohol 20.00 25 213 0.93 0.34 0.13 0.47 (0.39-0.56) 0.47 (0.37-0.59) 0.47 (0.34-0.64)
Note: Compositae mix 5% contained the following extracts and single compounds, respectively: Anthemis nobilis 1.2%, Chamomilla recutita 1.2%, Achillea
millefolium 1%, Tanacetum vulgare 1%, Arnica montana 0.5%, and parthenolide 0.1%; in the 2.5% version, the same ingredients were included at half the
concentration; 6% contained Tanacetum vulgare 1%, Arnica montana 0.5%, Tanacetum parthenium 1%, Matricaria chamomilla 2.5%, and Achillea millefolium
1%. All allergens in petrolatum (pet.). conc., concentration in %; IR, irritant; MDBGN, Methyldibromo glutaronitrile.
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had been tested with both carba mix and ZDEC, but 15 549 with both
thiuram mix and ZDEC. Among these, 71 reacted to both allergen
preparations, 325 only to thiuram mix, and 19 to ZDEC, but not to
thiuram mix.
Regarding reactivity to sesquiterpene lactone (SL) mix vs the
three different Compositae mixes, 3305 patients were tested with SL
mix and Compositae mix 2.5% pet.; of these, 10 reacted positive to
both, 6 only to Compositae mix, and 9 only to SL mix. Fewer patients
(n = 1154) had been tested with both SL mix and Compositae mix 5%
pet., with 0 reacting positive to both, 2 only to Compositae mix 5%,
and 4 only to SL mix. Compositae mix 6% pet. had not been tested in
parallel with SL mix in a significant number of patients. Finally, cross-
reactivity between colophonium and oil of turpentine was examined.
Both allergens had been applied in 14 150 patients, with positive
TABLE 4 Patch test results (day 3 to day 5) with the TRUE Test allergens, 2015 to 2018, in those six departments (partially) using it
Allergen Conc. (μg/cm2) Tested % ?+/IR % + % ++/+++ % positive (95% CI)
Metals
Potassium dichromate 54 2591 0.72 1.58 1.54 3.13 (2.49-3.87)
Cobalt (II) chloride 20 2588 1.32 3.63 2.01 5.64 (4.78-6.6)
Nickel (II) sulfate 200 2571 3.04 8.95 12.37 21.31 (19.75-22.95)
Fragrances
Fragrance mix I 500 2592 1.03 2.35 1.43 3.78 (3.08-4.59)
Myroxylon pereirae (balsam of Peru) 800 2591 0.47 1.47 0.73 2.2 (1.67-2.84)
Preservatives
Formaldehyde 180 2592 0.76 0.81 0.35 1.16 (0.78-1.65)
MCI/MI 4 2593 0.27 2.58 6.44 9.02 (7.95-10.19)
Paraben mix 1000 2592 0.53 0.23 0.12 0.35 (0.16-0.66)
Quaternium-15 100 2592 0.45 0.73 0.5 1.23 (0.85-1.74)
Diazolidinyl urea 550 2581 0.4 0.35 0.08 0.43 (0.21-0.76)
Imidazolidinyl urea 600 2578 0.2 0.23 0.08 0.31 (0.13-0.61)
Quinoline mix 190 1082 0.18 0.18 0.37 (0.1-0.94)
Thiomersal 7 2591 0.8 1.35 1.16 2.51 (1.94-3.19)
Medicaments, excipients
Caine mix III (benzo-, dibu-, tetracaine) 630 2591 0.53 0.62 0.73 1.35 (0.94-1.87)
Budesonide 1 2590 1.46 0.19 0.19 0.39 (0.19-0.71)
Tixocortol pivalate 3 2594 1.16 0.42 0.42 0.85 (0.53-1.28)
Hydrocortisone-17-butyrate 20 2241 3.19 0.18 0.13 0.31 (0.13-0.64)
Neomycin sulfate 600 2591 0.2 0.27 0.15 0.42 (0.21-0.76)
Lanolin (wool) alcohols 1000 2595 1.2 0.89 0.12 1 (0.66-1.46)
Rubber additives
Thiuram mix 27 2590 1.06 1.2 0.85 2.05 (1.54-2.67)
p-Phenylenediamine (black rubber) mix 75 2590 0.73 0.46 0.46 0.93 (0.59-1.38)
Mercapto mix (CBS, MBTS, MOR) 75 2591 0.4 0.62 0.5 1.12 (0.75-1.6)
Mercaptobenzothiazole 75 2588 0.27 0.46 0.31 0.77 (0.47-1.19)
Carba mix 250 2578 2.7 2.56 1.01 3.57 (2.89-4.36)
Resins/glues
Colophonium 1200 2591 0.54 1.27 0.96 2.24 (1.7-2.88)
Epoxy resin 50 2587 1.19 1.04 1.04 2.09 (1.57-2.71)
PTBFR 45 2591 0.93 1.39 0.89 2.28 (1.74-2.93)
Other
p-Phenylenediamine 90 2570 0.72 1.48 2.18 3.66 (2.97-4.46)
Ethylenediamine-HCl 50 2591 0.49 0.35 0.46 0.81 (0.5-1.24)
Abbreviations: CBS, N-Cyclohexylbenzothiazyl sulfenamide; MBTS, Dibenzothiazyl disulfide; MCI, methylchloroisothiazolinone; MDBGN, methyldibromo
glutaronitrile; MI, methylisothiazolinone; MOR, 2-(4-Morpholinylmercapto)benzothiazol; PTBFR, p-tert-butylphenol formaldehyde resin.
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reactions in 65 (0.46%) to both allergen preparations, and in
492 (3.48%) only to colophonium and 48 (0.34%) only to oil of turpen-
tine (OR 37.3, P < .0001). Oil of turpentine could be viewed as a fra-
grance allergen, owing to its use as raw fragrance material. Cross-
reactivity to both fragrance mix (FM) I and Myroxylon pereirae resin
was less, with ORs of 6.2 and 5.2, respectively, but still highly signifi-
cant (both P < .0001).
Altogether, 25 141 patients were routinely tested with both lano-
lin (wool) alcohols and cetearyl (cetostearyl) alcohol, almost exclusively
in the IVDK departments and in the UK. While the prevalence of posi-
tive reactions to lanolin alcohols was not significantly different
between IVDK and UK departments (P = .4), that of positive reactions
to cetearyl alcohol was 0.7% in the former vs 0.2% in the latter
(P < .0001). Co-reactivity between the two emulsifiers was limited,
with 24 (0.1%) patients reacting to both, 498 (1.98%) only to lanolin
alcohols, and 95 (0.38%) only to cetearyl alcohol.
Propolis is a long-standing constituent of the baseline series in
German-speaking countries. The prevalence of positive reactions was
4% in the participating departments of the three countries (Austria,
Germany, and Switzerland) which are also members of the IVDK, and
1% in the others testing it, namely, departments from Italy, Lithuania,
UK, and, to a limited extent, The Netherlands and Poland, P < .0001.
While propolis is not a fragrance allergen, cross-reactivity to FM I
(OR 5.6) and M pereirae (OR 7.5) was substantial (both P < .0001).
Finally, patch test results with the TRUE Test are shown in
Table 4; the departments using this test system as a part of their base-
line patch test work-up supplemented this with investigator-loaded
test allergens to (mostly) conform with the EBS. These latter results
are included in Table 2, for example, concerning MI.
4 | DISCUSSION
The present analysis of routine surveillance data collected by the
ESSCA follows up on previous reports and is a continuation of a series
of similar reports on data from 2002/2003,16 2004,17 2005/2006,18
2007/2008,19 2009 to 2012,20-25 and lastly, 2013/2014.3 The chang-
ing patterns of contact allergy can therefore be observed and inter-
preted, albeit from the background of a partly changing contribution
to the network, which needs to be considered.
With increasing geographical contribution to the ESSCA network,
extreme proportions of the characteristics of patients as described by
the MOAHLFA index have partly increased, while the changes in the
mean values are less pronounced. For instance, compared with the
first reporting period, in which a table identical to Table 1 had been
incorporated,16 the share of males slightly dropped from 37.1% to
32.9%, whereas the percentage of patients with occupational dermati-
tis increased slightly from 13.1% to 16.1%. In accordance with obser-
vations elsewhere, but not quite as marked,26 there was a trend of
patients being older in the recent period, with a share of 62.6% aged
40 and older, compared with 57.8% in the first ESSCA report. The
most striking increase was seen in the proportion of patients with a
history or current diagnosis of atopic dermatitis, from 18.0% to the
current figure of 27.5%. However, there is no uniform definition of
(a history of) atopic dermatitis, leading to considerable heterogeneity
of this characteristic, and thus difficulties in interpreting this change,
also owing to the changing and expanding nature of ESSCA. Con-
cerning anatomical sites of dermatitis, a shift from leg (9.1% to 5.3%)
to face (from 13.4% to 17.9%) and a largely stable share of hand der-
matitis (28.7% vs 27.0%) was observed. A decrease of leg dermatitis
may be due to a change of treatment paradigms, with less allergenic
products used in more recent times.27 The increase in face dermatitis
can, at least partly, be attributed to the recent epidemic of MI sensiti-
zation with many cosmetic-related cases of face dermatitis.28
The overall yield of the baseline series, in terms of at least one
positive reaction to one of its allergens, had been suggested as
another descriptor of a patch tested patient population.11 However,
as this measure summarizes rather complex effects, as more exten-
sively discussed in Uter et al,20 its interpretation is not straightfor-
ward; notwithstanding, the broad range of positivity does stimulate
speculation.
4.1 | European baseline series (version 2015)
Taken together, and certainly dominated by nickel, the three metals
included in the EBS most commonly cause contact allergies. Age-
stratified results indicate a lower prevalence of nickel allergy in the
youngest age group, compared with the quite broadly defined middle
age group. This may reflect to some extent a, albeit limited, decline of
nickel contact allergy.29 However, despite a considerable success of
preventive efforts, nickel exposure prevention needs further improve-
ment.30 The prevalence of chromium contact allergy is lowest in the
youngest age group; however, because chromium is a less ubiquitous
allergen, the success of prevention (reduction of hexavalent chromium
in cement and more recently, in leather) should best be reviewed in
particularly exposed subgroups, for example, in the building industry31
and in patients with shoe (foot) dermatitis. Cobalt, in contrast to the
other two metals, does not display any age pattern. Given the general
difficulty in identifying clinical relevance for sensitization to cobalt,32
it is difficult to identify relevant exposures which need to be
addressed by further research and, ultimately, prevented.
Fragrances are the next most common group of substances or
mixtures causing contact allergy. Positive patch test reactions to FM I
show a well-known age gradient,33 possibly owing to the life-long
cumulative exposure and steadily increasing risk of sensitization. It is
unclear, at least by just looking at the FM I results, whether the lower
prevalence in the younger patients also reflects self-regulatory con-
centration restrictions concerning FM I constituents in cosmetics
taken in the past. A similar pattern is seen for FM II and its main aller-
genic constituent, hydroxyisohexyl 3-cyclohexene carboxaldehyde
(HICC). In view of the recent ban of HICC, and the de facto ban of
Evernia prunastri (oak moss) due to the restrictions on (chlor)atranol,34
a re-design of the mixes could be considered in due time, to adapt
these to the currently relevant exposure conditions in Europe. The
age gradient of positive reactions to M. pereirae (balsam of Peru) is
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even more marked than that of FM I. This “ill-defined natural fra-
grance mix” is an apparently important, but also enigmatic allergen,
concerning the consequences of a positive patch test for the patient,
as recently reviewed by de Groot.35
The dramatic increase of contact allergy prevalence to MI and,
parallel to this, to the mixture methylchloroisothiazolinone (MCI)/MI
3:1 in the recent past, and the decline since 2013/2014 have been
repeatedly reported and discussed,9,36 and shall not be expanded on
here. The fact that MI 0.02 and 0.05% aq. elicited a slightly higher
share of positive reactions than MI 0.2% as recommended appears
counter-intuitive, but should not be overinterpreted: (a) different sub-
groups of patients had been patch tested, and (b) the prevalences are
not significantly different, if overlapping 95% CIs are considered. The
lesser decrease of MI 0.2% aq., as compared with 0.05% aq., during
the study period characterized by a marked decrease of MI sensitiza-
tion prevalence may have partly contributed to the seemingly similar
yield of patch reactions with the two concentrations. The same holds
true for formaldehyde, while MCI/MI and methyldibromo glu-
taronitrile (MDBGN) show a pattern one would expect. In 2005, the
European Union (EU) banned the use of MDBGN in leave-on cosmetic
products, and then in 2007 banned it also in rinse-off cosmetic prod-
ucts. The fact that patients up to the age of 30 years had positive
patch test reactions to MDBGN in 2015 to 2018 (Table S3) may imply
that these individuals were all sensitized to MDBGN in cosmetics by
the age of 20 years. Alternatively, or additionally, there may be expo-
sure from rogue cosmetics, unregulated use in medical devices, cos-
metic products marketed as medical devices, undeclared exposure,37
or noncosmetic sources such as paints, glues, or technical fluids,
although such broad exposure to MDBGN is largely unknown pres-
ently. From this background, reporting on patients with currently rele-
vant contact allergy to MDBGN37,38 is encouraged. A cautionary note
is that false-positive reactions particularly to MDBGN 0.5% pet. may
occur.39 As sensitization to paraben mix and quaternium-15 is now
uncommon (Table 2), the continued inclusion of these allergens in the
EBS may be only marginally justifiable.
The EBS contains two corticosteroids assumed to cover different
antigenic classes,40 namely, budesonide and tixocortol pivalate. A
Spanish multicentre study involving 3699 consecutively patch tested
patients added six other corticosteroids (methylprednisolone
aceponate, mometasone furoate, prednicarbate, clobetasol propio-
nate, betamethasone 17-valerate, and betamethasone 17, 21-dip-
ropionate). Overall, 1.46% (n = 54) showed a positive reaction to at
least one of the eight corticosteroids and, among these, 39 to one of
the six additional corticosteroids. Interestingly, 24 of those 39 were
not positive to any of the two screening markers; hence, contact
allergy would have been missed when relying solely on these.41 In
other words, the two EBS markers failed to detect corticosteroid
allergy in about 40% of the patients in that study, which probably
depends on country- or region-specific exposure/prescription. Of
note, the Spanish study used a day 7 reading, which was mostly lac-
king in the present data, and in the outcome definition, which must be
regarded as a shortcoming leading to underestimation of the sensitiza-
tion prevalence particularly of the corticosteroids by up to 30%.42 It is
recommended to test with a full series of corticosteroids in case aller-
gic contact dermatitis to these is suspected.
Clioquinol contact allergy has become a rarity, justifying its recent
elimination from the EBS.4 Benzocaine was replaced by Caine mix III
in 2019, and at least in the present analysis the detection rate of the
latter is higher; however, further patch test studies on Caine mix III
are warranted to further assess its diagnostic validity and the clinical
relevance of positive reactions. Neomycin sulfate is a topical antibiotic
rarely used in some countries, while it is a popular, sometimes over-
the-counter remedy, in others; this heavily impacts the prevalence of
sensitization. From this background, the German Contact Dermatitis
Research Group decided several years ago to remove neomycin sul-
fate from its baseline series; however, in other countries, and certainly
the United States, it is still an important part of the baseline series.43
Compared with thiuram mix, sensitization to the other rubber
allergens, including N-isopropyl-N0-phenyl-p-phenylenediamine, is rel-
atively rare. Of note, thiurams, including the mix, are considered to
detect contact allergy to dithiocarbamates, as corresponding thiurams
and dithiocarbamates constitute redox pairs.44 Positive patch test
reactions to the benzothiazoles are almost twice as common in the
youngest, compared with the oldest age group, likely pointing to occu-
pational exposure and sensitization, for example, in the healthcare
sector, or perhaps to fashion-related exposures. In general, if (occupa-
tional) exposure to rubber additives is suspected to cause allergic con-
tact dermatitis, testing with a dedicated rubber series, pieces of
rubber products, or ultrasonic extracts thereof is indicated.44 Patch
testing with rubber constituents has been discussed in-depth
elsewhere,25,44 particularly the problem of irritant patch test reactions
to 1,3-diphenylguanidine,45 which has been found, at the same time,
to be an important allergen in synthetic rubber gloves.46
The sensitization prevalence of PPD is largely stable, with a pre-
ponderance of females (Table 2) and a weak variation across age
groups (Table S2). Contact allergy to PPD is often related to exposure
to oxidative hair dyes.47 Hence, a much reduced share of PPD-
containing hair dye products and replacement with only partially
cross-reacting PPD derivatives recently observed at least in Ger-
many48 could be expected to contribute to a lessening of sensitization
frequency. The marked cross-reactivity of PPD with TDM, owing to
the presence of Disperse Orange 3 in the latter, has been confirmed
in the present data. To avoid unnecessary, possibly strong, or extreme
patch test reactions, a TDM without Disperse Orange 3 should be
evaluated.49
The frequency of sensitization to epoxy resin largely remained
stable over the previous years;3 contact allergy is mostly observed in
patients with occupational dermatitis.50 This suggests that further
efforts to improve occupational hygiene are necessary, especially in
(spray) painting and at construction sites or in pipe relining.51
4.2 | Additional, consecutively tested allergens
Among the allergens still not part of the EBS in the study period, prop-
olis and caine mix III, along with 2-hydroxyethyl methacrylate, have
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been incorporated in the 2019 version of the EBS. With a sensitiza-
tion prevalence of around 3%, remarkably similar between the sexes
and with just a slight increase with age, propolis seems indeed a
worthwhile addition. Accordingly, propolis had been identified as an
emerging allergen in a recent analysis of long-term data from the
IVDK (of which the present data sample constitutes a fraction, see the
“Methods” section).9 A comparison between results from “IVDK coun-
tries” and the remaining countries testing with propolis shows a highly
significant difference in prevalences, with a prevalence of 1% in the
latter, illustrating the well-known geographical variation of contact
allergy to this natural product.19 Further results are awaited, together
with information on clinical relevance and exposure in patients with
positive patch test reactions. With a prevalence of positive reactions
well above 1%, caine mix III also seems a worthwhile addition or
rather replacement in the EBS; notwithstanding further studies, for
example, comparing mix with break-down results. 2-Hydroxyethyl
methacrylate had not been consecutively tested in a sufficient number
of departments to warrant presentation. However, owing to the mas-
sively increased exposure in terms of cosmetic acrylic nail usage, con-
tact allergy to this allergen is expected to escalate.52
Data suggest that SL mix alone is insufficient as a screen to diagnose
Compositae allergy, but the ideal combination is not yet established.
Some suggest a combination with Compositae mix II 2.5% pet. and par-
thenolide 0.1% pet.53 However, while the original Compositae mix I 5%
pet. induced active sensitization, others feel that the 5% concentration
of the Compositae mix II is not sensitizing and contains parthenolide
0.1%54 rather than feverfew extract that was in the mix I.
The question as to whether different formaldehyde releasers,
including quaternium-15, which is a longstanding constituent of the
EBS, should be tested in addition to formaldehyde (ideally 2% aq.) has
been addressed by another, dedicated analysis and shall not be dis-
cussed here.55 The present results with the different formaldehyde
releasers are largely similar to the more detailed, department-wise
analysis of 2013/2014 data.56 The mixture of MDBGN and
2-phenoxyethanol 1:4 (eg, Euxyl K 400 as trademark) is still tested to
a limited extent by some departments. Iodopropynyl butylcarbamate
(IPBC) 0.2% pet., tested in more than 20 000 consecutive patients,
caused over 1% positive, mostly weak positive, reactions and about
three times as many doubtful or irritant reactions. However, other
studies found a lower sensitization prevalence (eg, 0.53%).57 IPBC lib-
erates iodine, which has also been supported by observing simulta-
neous contact allergy to IPBC and iodine.58 Owing to possible
endocrine interference, use concentrations are restricted to between
0.02% in rinse-off products and 0.0075% in deodorants/antiperspi-
rants for many years (SCCNFP/0826/04, EU Cosmetics Regulation,
Annex V/56). It would be of interest to further investigate IPBC
regarding the clinical relevance of (weak) positive patch test reactions.
Similar to propolis, cetearyl alcohol also exhibits significant geographi-
cal differences, albeit on a much lower level, presently not justifying
inclusion into the EBS. While sodium metabisulfite yields a consider-
able number of positive reactions (Table 3) and has thus been rec-
ommended to be added to the EBS,4 fusidic acid seems to be a rare
allergen not warranting consecutive testing.
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